PAM
HEPA

PVG Asset Management’s Hepion Pharmaceuticals HEPA Stock Holding History

PVG Asset Management’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-61
Closed -$47.5K – 43
2023
Q1 		$47.5K Hold
61
– – 0.15% 35
2022
Q4 		$18.4K Sell
61
-47
-44% -$19.9K 0.08% 34
2022
Q3 		$54.5K Buy
+108
New +$65.9K 0.21% 30
2021
Q4 		$114K Buy
100
+48
+92% +$65.7K 0.42% 39
2021
Q3 		$79.5K Sell
52
-138
-73% -$221K 0.24% 37
2021
Q2 		$375K Buy
190
+176
+1,257% +$322K 1.17% 28
2021
Q1 		$26K Buy
+14
New +$30.7K 0.08% 45

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PVG Asset Management's HEPA Position: Q2 2023 in Review

PVG Asset Management sold out of Hepion Pharmaceuticals (HEPA) in Q2 2023, closing a stake of 61 shares — an estimated $47.5K sold.

PVG Asset Management first reported a position in HEPA in Q1 2021 and held it in 7 quarters. The position peaked at $375K in Q2 2021. 16 funds tracked by Wall St. Rank hold HEPA as of Q2 2023.

  • PVG Asset Management reported no remaining Hepion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • PVG Asset Management sold 61 Hepion Pharmaceuticals shares in Q2 2023, an estimated $47.5K.
  • PVG Asset Management first reported a position in Hepion Pharmaceuticals in Q1 2021 and held it in 7 quarters.
  • PVG Asset Management's Hepion Pharmaceuticals position peaked at $375K in Q2 2021.
  • 16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2023.

Based on PVG Asset Management's 13F filing for Q2 2023, filed 31 Jul 2023.